HKU-Pasteur Research Centre, The University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China.
PLoS One. 2012;7(11):e43596. doi: 10.1371/journal.pone.0043596. Epub 2012 Nov 2.
Serological studies for influenza infection and vaccine response often involve microneutralization and hemagglutination inhibition assays to evaluate neutralizing antibodies against human and avian influenza viruses, including H5N1. We have previously characterized lentiviral particles pseudotyped with H5-HA (H5pp) and validated an H5pp-based assay as a safe alternative for high-throughput serological studies in BSL-2 facilities. Here we show that H5-HAs from different clades do not always give rise to efficient production of H5pp and the underlying mechanisms are addressed.
METHODOLOGY/FINDINGS: We have carried out mutational analysis to delineate the molecular determinants responsible for efficient packaging of HA from A/Cambodia/40808/2005 (H5Cam) and A/Anhui/1/2005 (H5Anh) into H5pp. Our results demonstrate that a single A134V mutation in the 130-loop of the receptor binding domain is sufficient to render H5Anh the ability to generate H5Anh-pp efficiently, whereas the reverse V134A mutation greatly hampers production of H5Cam-pp. Although protein expression in total cell lysates is similar for H5Anh and H5Cam, cell surface expression of H5Cam is detected at a significantly higher level than that of H5Anh. We further demonstrate by several independent lines of evidence that the behaviour of H5Anh can be explained by a stronger binding to sialic acid receptors implicating residue 134.
We have identified a single A134V mutation as the molecular determinant in H5-HA for efficient incorporation into H5pp envelope and delineated the underlying mechanism. The reduced binding to sialic acid receptors as a result of the A134V mutation not only exerts a critical influence in pseudotyping efficiency of H5-HA, but has also an impact at the whole virus level. Because A134V substitution has been reported as a naturally occurring mutation in human host, our results may have implications for the understanding of human host adaptation of avian influenza H5N1 viruses.
流感感染和疫苗反应的血清学研究通常涉及微量中和和血凝抑制试验,以评估针对人源和禽流感病毒(包括 H5N1)的中和抗体。我们之前已经对带有 H5-HA(H5pp)的慢病毒颗粒进行了特征描述,并验证了基于 H5pp 的检测方法可作为在 BSL-2 设施中进行高通量血清学研究的安全替代方法。在此,我们表明,来自不同谱系的 H5-HA 并不总能导致 H5pp 的有效产生,并解决了潜在的机制。
方法/发现:我们进行了突变分析,以描绘负责将 A/Cambodia/40808/2005(H5Cam)和 A/Anhui/1/2005(H5Anh)的 HA 有效包装到 H5pp 中的分子决定因素。我们的结果表明,受体结合域 130 环中的单个 A134V 突变足以使 H5Anh 具有有效产生 H5Anh-pp 的能力,而相反的 V134A 突变则极大地阻碍了 H5Cam-pp 的产生。尽管 H5Anh 和 H5Cam 在总细胞裂解物中的蛋白表达相似,但 H5Cam 的细胞表面表达水平明显高于 H5Anh。我们还通过几条独立的证据进一步证明,H5Anh 的行为可以通过与唾液酸受体的更强结合来解释,这暗示了残基 134。
我们已经确定 H5-HA 中的单个 A134V 突变是有效掺入 H5pp 包膜的分子决定因素,并阐明了潜在的机制。由于 A134V 突变导致与唾液酸受体的结合减弱,不仅对 H5-HA 的假型效率产生关键影响,而且对整个病毒水平也有影响。由于 A134V 取代已被报道为人类宿主中的自然发生突变,我们的结果可能对理解禽流感 H5N1 病毒的人类宿主适应性具有重要意义。